FACT-P Functional Assessment of Cancer Therapy – Prostate For patients with Prostate cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Prostate (FACT-P) is a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer. It was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). MEASURE NAME: Functional Assessment of Cancer Therapy – Prostate (FACT-P) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Prostate cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Prostate Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FPSI , NFPSI-17 , FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-P can be obtained by registering for permission. Users are not permitted to translate the FACT-P without permission from FACIT.org. Permission from FACIT.org to translate the FACT-P may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Beaumont, J., Butt, Z., Li, R., & Cella, D. Meaningful Differences and Validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. Cancer 2019; 125(11): 1877-1885. doi: 10.1002/cncr.31973. Beer, T., Miller, K., Tombal, B., Cella, D., DePhung, Holmstrom, S., Ivanescu, C., Skaltsa, K., & Naidoo, S. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. European Journal of Cancer 2017; 87: 21-29. doi: 10.1016/j.ejca.2017.09.035. Cella, D., Petrylak, D., Fishman, M., Teigland, C., Young, J., & Mulani, P. Role of quality of life in men with metastatic hormone-refactory prostate cancer: How does Astrsentan influence quality of life? European Urology 2006; 49: 781-789. doi: 10.1016/j.eururo.2005.12.05. Cella, D., Nichol, M., Eton, D., Nelson, J., & Mulani, P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health 2009; 12(1): 124-129. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K.J. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument. Urology 1997; 50(6): 920-928. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. PMID: 37269841; PMCID: PMC10641914. Orakwe, D., Tijani, K., Jeje, E., Ogunjimi, M., Rufus, W., & Alab, T. Bilateral Subcapsular Orchiectomy versus Bilateral Total Orchiectomy: Comparison of the Quality of Life Post‑Orchiectomy. Nigerian Postgraduate Medical Journal 2018; 25(1): 43-47. doi: 10.4103/npmj.npmj_169_17. Parker, C., Nilsson, s., Heinrich, D., Helle, S., O’Sullivan, J., Fosså, S., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D., Hoskin, P., Bottomley, D., James, N., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall’Oglio, M., Franzén, L., Coleman, R., Vogelzang, N., O’Bryan-Tear, C., Staudacher, K.., Garcia-Vargas, J., Shan, M., Bruland, Ø.., & Sartor, O. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. The New England Journal of Medicine 2013; 369(3): 213-223. doi: 10.1056/NEJMoa121375. Saad, F., Cella, D., Basch, E., Hadaschik, B., Mainwaring, P., Oudard, S., Graff, J., McQuarrie, K., Li, S., Hudgens, S. Lawson, J., Lopez-Gitlitz, A., Yu, M., Smith, M., & Small, E. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2018; 19(10):1404-1416. doi: 10.1016/ S1470-2045(18)30567-9. Sullivan, P. Nelson, J., Mulani, P., & Slee, D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research 2006; 15: 1297–1306. doi: 10.1007/s11136-006-0003-2. Vashistha, V., Singh, B., Kaur, S., Prokop, L., & Kaushik, D. The Effects of Exercise on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer: Systematic Review and Meta-analyses. European Urology Focus 2016; 2(3): 284-295. doi: 10.1016/j.euf.2016.02.011. Victorson, D., Beaumont, J, Rosenbloom, S., Shevrin, D, & Cella, D. Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P symptom index. Psycho-Oncology 2011; 20(9): 977-983. doi: 10.1002/pon.1817. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FPSI Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 7 Item Version LEARN MORE NFPSI-17 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

View all available languages for this measure. BACK FCSI Languages Afrikaans Arabic Bengali Bulgarian Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French Georgian German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Russian Serbian Slovak Spanish Swedish Tamil Telugu Thai Turkish Ukrainian Vietnamese

Download scoring documents for this measure. BACK peds FACIT-F Scoring Downloads Download DOC

Download this measure in English. BACK FACT-AntiA English Downloads Download PDF Download DOC

Download this measure in English. BACK FACT-CTCL English Downloads Download PDF Download DOC

FEnSI Functional Assessment of Cancer Therapy – Endometrial Symptom Index For patients with Endometrial cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FEnSI is a clinically meaningful patient-reported symptom index reflecting the symptoms and concerns identified as most important by diverse patients with endometrial cancer. MEASURE NAME: Functional Assessment of Cancer Therapy – Endometrial Symptom Index (FEnSI) VERSION: 2 NUMBER OF ITEMS: 23 PATIENT POPULATION: Endometrial cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical, Emotional, Treatment Side-Effects, Function and Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-En , FACT-Cx , FACT-O DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FEnSI can be obtained by registering for permission. Users are not permitted to translate the FEnSI without permission from FACIT.org. Permission from FACIT.org to translate the FEnSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Wenzel L., McKinney C., Jensen S., Peipert D., Ganatra S., Bredle J., Sisodia R., Doll K., Philp L., Arend R., Dholakia J., Cella D. Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).Gynecologic Oncology Volume 194, March 2025, pp. 137-144 https://doi.org/10.1016/j.ygyno.2025.02.020 Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-En Functional Assessment of Cancer Therapy – Endometrial LEARN MORE FACT-Cx Functional Assessment of Cancer Therapy – Cervix LEARN MORE FACT-O Functional Assessment of Cancer Therapy – Ovarian LEARN MORE

View all available languages for this measure. BACK FACT-G Languages Afrikaans Albanian Arabic Armenian Bengali Bosnian Bulgarian Burmese Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French Georgian German Greek Gujarati Haitian Creole Hebrew Hiligaynon Hindi Hungarian Icelandic Ilokano Indonesian Italian Japanese Kannada Kazakh Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Mongolian Montenegrin Nepali Norwegian Odia Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Sesotho Setswana Sinhala Slovak Slovene Spanish Swahili Swedish Tagalog Tamil Telugu Thai Tsonga Turkish Ukrainian Urdu Uzbek Vietnamese Wolof Xhosa Zulu

DMD Diarrhoea Management Diary For patients with metastatic breast cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the DMD measure: MEASURE NAME: Diarrhoea Management Diary (DMD) VERSION: 9 NUMBER OF ITEMS: 8 PATIENT POPULATION: Metastatic breast cancer patients 18 and older experiencing diarrhoea RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: FACIT-AD , NVMBQ , FACIT-D DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the DMD can be obtained by registering for permission. Users are not permitted to translate the DMD without permission from FACIT.org. Permission from FACIT.org to translate the DMD may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ. The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Res Treat . 2020 Oct;183(3):629-638. doi: 10.1007/s10549-020-05798-w. Epub 2020 Jul 27. PMID: 32720113; PMCID: PMC7497672. Abdullah M, Firmansyah M. Clinical Approach and Management of Chronic Diarrhea. Acta Med Indones 2013; 45:157-65. Atherton P, Halyard M, Sloan J, et al. Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer , 2013; 21:1193-9. Benson A III, Ajani J, Catalano R, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918–26. Cherny N. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. Pain Symptom Manage 2008; 36:413-23. Clark J, Talcott J. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001; 39:1118-30. Davidson-Homewood J, Norman A, Kūlchler T, et al. Development of a disease specific questionnaire to supplement a generic tool for QOL in colorectal cancer. Psycho-Oncol 2003; 12:675-85. Haddock M, Sloan J, Bollinger J, et al. Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial. J Clin Oncol 2007;25:1255-9. O'Cathain A, Thomas K. "Any other comments?" Open questions on questionnaires – a bane or a bonus to research? BMC Medical Research Methodology 2004; 4:25. Stein A. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2:51-63. Temple L, Bacik J, Savatta S, et al. The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer. Dis Colon Rectum 2005;48:1353-65. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1:79. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translating adaptation. Value Health 2005; 2:94-104. LICENSE THIS MEASURE Related Measures Related Measures FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE NVMBQ Nausea and Vomiting Management Barriers Questionnaire LEARN MORE FACIT-D Functional Assessment of Chronic Illness Therapy - Diarrhea LEARN MORE

Download scoring documents for this measure. BACK FACIT-D Scoring Downloads Download DOC

Download scoring documents for this measure. BACK COST Scoring Downloads Download DOC

Download this measure in English. BACK FACIT-CD English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FACIT-CD Scoring Downloads Download DOC